You are here: Home » News-CM » Companies » News
Business Standard

Cipla launches generic Nintedanib for treatment of Idiopathic Pulmonary Fibrosis

Capital Market 

Cipla announced that it has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Available as 100 mg and 150 mg capsules, it will be marketed under the brand name Nintib. This launch marks yet another milestone in Cipla's decade-long commitment to treat IPF, a rare lung disease that impacts ten in one lakh people.

Cipla's journey in IPF began in 2010 with the introduction of Pirfenex, the world's first generic Pirfenidone and the first ever approved drug for IPF in India. Further to this, Cipla reduced the cost of its IPF therapy by 40% in 2013 to provide patient-access to this critical treatment.

In line with its endeavour of enabling effective and affordable management of IPF, Cipla's Nintib is priced at Rs. 69 (100 mg) and Rs. 85 (150 mg) per capsule.

IPF is a chronic progressive form of lung disease with an average survival rate of three to five years if left untreated. It is characterized by scarring in the lungs, wherein the lung tissue becomes stiff and thick. This interferes with a person's ability to breathe and reduces oxygen supply to the blood, resulting in shortness of breath. Over the past ten years, Cipla has played a pivotal role in creating awareness on the diagnosis and treatment of IPF amongst the medical fraternity.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, October 20 2020. 19:33 IST